Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics Ltd. has appointed Dr. Rebecca McQualter as its new COO, bringing her extensive pharmaceutical industry experience from Novartis, Amgen, and GSK to the Australian cell therapy leader. Her robust background includes a PhD in Cell Therapy and Regenerative Medicine, and she has demonstrated strong leadership in developing commercial partnerships and driving sales growth in previous roles. Dr. McQualter’s addition is set to bolster Chimeric’s growth as they advance their portfolio of innovative cancer cell therapies.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
